Therapeutic Anticoagulation Dosing Regimens
For therapeutic anticoagulation in this patient, initiate with either low-molecular-weight heparin (LMWH) as the preferred agent or unfractionated heparin (UFH), followed by warfarin bridging to achieve an INR of 2.0-3.0. 1, 2
Initial Anticoagulation Options
Low-Molecular-Weight Heparin (Preferred)
LMWH is preferred over UFH due to superior efficacy, safety profile, and ease of administration. 2
Dosing regimens:
- Enoxaparin: 1 mg/kg subcutaneously every 12 hours OR 1.5 mg/kg once daily 1, 2, 1
- Dalteparin: 100 U/kg every 12 hours OR 200 U/kg once daily 1
- Tinzaparin: 175 U/kg once daily 1
Key advantages of LMWH:
- More predictable anticoagulation without routine monitoring 2
- Lower risk of heparin-induced thrombocytopenia (HIT) - platelet monitoring not routinely needed 2
- Can be administered outpatient 2
Important caveat: Avoid LMWH if creatinine clearance <30 mL/min due to drug accumulation 1, 2. In renal failure, switch to UFH or adjust dose based on anti-factor Xa levels.
Unfractionated Heparin (Alternative)
Use UFH when LMWH is contraindicated (severe renal failure, high bleeding risk requiring rapid reversal, or concern for HIT).
Dosing:
- IV bolus: 80 U/kg, then continuous infusion at 18 U/kg/hour 1, 2, 3
- Subcutaneous: 333 U/kg initial dose, then 250 U/kg twice daily 2
Monitoring requirements:
- Target aPTT ratio of 1.5-2.5 (corresponding to anti-factor Xa level 0.3-0.7 IU/mL) 1, 2, 3
- Check aPTT 4-6 hours after bolus, then 6-10 hours after any dose adjustment 4
- Critical: Monitor platelets every 2-3 days from day 4-14 to screen for HIT (risk up to 5%) 2
Dose adjustment nomogram for UFH: 3
- aPTT <35 sec: Give 80 U/kg bolus, increase infusion by 4 U/kg/hour
- aPTT 35-45 sec: Give 40 U/kg bolus, increase infusion by 2 U/kg/hour
- aPTT 46-70 sec: No change
- aPTT 71-90 sec: Reduce infusion by 2 U/kg/hour
- aPTT >90 sec: Stop infusion for 1 hour, then reduce by 3 U/kg/hour
Fondaparinux (Alternative)
- <50 kg: 5 mg once daily
- 50-100 kg: 7.5 mg once daily
100 kg: 10 mg once daily
Contraindicated if creatinine clearance <30 mL/min. 2 Negligible HIT risk—no platelet monitoring needed. 2
Warfarin Bridging
Start warfarin on day 1 or 2 of parenteral anticoagulation—do not delay. 5, 6
Initial dosing:
- Standard patients: 5-10 mg daily for first 2 days 6
- Elderly, debilitated, or those with genetic variations (CYP2C9, VKORC1): Start with 2-5 mg daily 6
Overlap requirements:
- Continue parenteral anticoagulant for minimum 5-7 days AND until INR ≥2.0 for 2 consecutive days 1, 2
- Target INR: 2.0-3.0 (target 2.5) 1, 6
Monitoring:
Special Considerations
Cancer patients: Consider extended LMWH monotherapy rather than warfarin transition, as LMWH shows survival advantage in this population. 1, 7 Use dalteparin 200 U/kg once daily for 1 month, then 150 U/kg once daily for long-term therapy. 1
Pregnancy: LMWH is preferred throughout pregnancy as warfarin crosses the placenta and causes embryopathy. 8 UFH is an alternative.
Obesity (>120 kg): Optimal enoxaparin dosing unclear—consider twice-daily dosing (1 mg/kg every 12 hours) over once-daily. 1
Common pitfall: Starting warfarin without adequate parenteral anticoagulation overlap increases thromboembolism risk 3-fold. 3 Always maintain therapeutic parenteral anticoagulation until INR is therapeutic for at least 24-48 hours.